Savings & Resources for Latuda® (lurasidone HCl) | HCP Resources

Dr. Smith's Dashboard

Sunovion Services

Request complimentary samples of LATUDA® (lurasidone HCl) tablets for your patients

ORDER YOUR SAMPLES NOW

Need support? Ask Sunovion Answers for information about LATUDA® (lurasidone HCl)

 

A dedicated team is available 7 days a week, from 8 AM to 12:00 midnight ET, to answer patient's calls at 1-855-552-8832

LEARN MORE

Most Viewed

Tools and resources to help you and your practice

Insights from your peers

Hear from your peers about bipolar depression, the challenges of diagnosis, and more. These insights can help your practice and your patients.

What is bipolar depression?

Identifying bipolar depression is challenging

By the book: diagnosis of bipolar depression

Mixed messages

What is bipolar depression?

Identifying bipolar depression is challenging

By the book: diagnosis of bipolar depression

Mixed messages

Featured experts are paid consultants of Sunovion.

Tools for you and your patients

These downloadable tools have been designed for physicians, nurse practitioners, patients, and caregivers alike. They are meant to aid in treatment and dialogue.

Tools-MDQ

Mood Disorder Questionnaire

If you think your adult patient may be struggling with symptoms of bipolar depression, print this form for your patient. Once complete, review the answers with your patient to start a deeper conversation. The Mood Disorder Questionnaire is appropriate for use with patients 18 and older.

Tools-DMM

Daily Mood Monitor

A Daily Mood Monitor is a valuable resource to track and understand how your patients are feeling on a daily basis. Print a few copies for your patient to fill out. On the next visit with your patient, review their information and have a real conversation about their symptoms and experiences.

Tools-Latuda-Brochure

LATUDA Patient and Caregiver Brochure

This downloadable tool provides basic information about bipolar depression and getting started on treatment with LATUDA. Additionally, there are tips and tools to help patients work with the treatment team, as well as guidance for caregivers helping a patient cope with bipolar depression.

Tools-Signs-BPD

Signs it May Be Bipolar Depression

Being able to recognize signs of bipolar depression may help your adult patients discuss their condition with you. If you believe your patient may be experiencing the symptoms of bipolar depression, print and review this tool with your patient and their caregiver.

Tools-Things-to-Know

Things to Know About LATUDA

When prescribing LATUDA for your adult patients with bipolar depression, print and share this helpful tool with both patient and caregiver during their office visit. The information includes how to take LATUDA, as well as things to remember while they are taking their medication. 

Tools-Exam-Room-Tool

Bipolar Depression Exam Room Discussion Tool

This brochure provides a brief overview of many of the facets of bipolar depression including how bipolar differs from unipolar depression. There are also tips to help adult patients and caregivers discuss signs, symptoms, and history with their physician.

Tools-Rating-Scales-Guide

Rating Scales: Reference Guide

This pocket reference was designed to help you and your staff better understand and evaluate clinical evidence for the use of medications to treat bipolar disorder. This guide includes a review of rating scales as well as safety measures that are often included in medication labels.

Tools-Now-Your-Talking-Guide

"Now You're Talking" Discussion Guide

Specifically designed for patients and caregivers, this discussion guide provides questions geared toward the journey itself. Whether newly diagnosed, just getting started or currently on LATUDA, or taking LATUDA for a while, the guide can be customized for your patient.

One way your patients can save on LATUDA

Request LATUDA Copay Savings Cards for your patients

Order packs of 10 cards to help eligible patients save on their LATUDA prescription copays*

  • Copays as little as $15* a month
  • Patients can save up to $400 on every LATUDA prescription fill for up to 12 monthly prescriptions per calendar year
  • Up to $4,800 total savings possible each year
  • Exclusions apply and copay amounts may vary. See terms and conditions below

*Must meet eligibility requirements. For commercially insured patients, this Copay Savings Card covers out-of-pocket expenses greater than $15 per prescription, with up to a maximum benefit of $400 for a 30-day prescription fill. Cash-paying patients will save up to $400 off the cost of their prescription after paying the first $15.
 


Available samples for trial in your appropriate patients with bipolar depression


Copay Savings Card Terms and Conditions

By using this card, you acknowledge that you currently meet the following eligibility requirements:

  • You must be 18 years of age or older to accept this offer. This offer is valid only for eligible patients and legal guardians of eligible patients. Patients must have a valid prescription for LATUDA within LATUDA’s approved indications
  • Offer not valid if prescription is paid in part or full by any state or federally funded health care program, including but not limited to Medicare, Medicaid, VA, DOD or TRICARE, or where prohibited by law
  • This card is valid for up to $400 off a prescription fill for up to a 30-day supply. The card is further limited to twelve (12) qualifying prescription fills
  • Offer is limited to one per person and may not be used with any other offer
  • This program is not health insurance. The amount of the benefit cannot exceed the patient’s out-of-pocket expenses. Acceptance of this offer must be consistent with the terms of any drug benefit provided by a health insurer, health plan, or other third-party payer. If requested or required by any such payer, the patient must report the use of this card. The patient must deduct the value of the savings received under this program from any reimbursement request submitted to the patient’s insurance plan, either directly or on the patient’s behalf.
  • For California and Massachusetts residents, benefits pursuant to this card will terminate automatically upon the introduction of a therapeutically equivalent product
  • Offer valid only in the United States and Puerto Rico. Void where prohibited by law, taxed or restricted
  • Sunovion reserves the right to rescind, revoke, or amend this offer at any time without notice. This offer is not transferable and may not be sold, purchased or traded, or offered for sale, purchase or trade

To the Patient: You must present this card to the pharmacist along with your prescription to participate in this program. If you have any questions regarding your eligibility or benefits, or if you wish to discontinue your participation, call Sunovion Answers at 1-855-5LATUDA (1-855-552-8832) anytime between 8 AM–12 midnight ET. By using this card, you are certifying that you understand the enclosed program rules, regulations, and terms and conditions; you have not submitted and will not submit a claim for reimbursement under any federal, state, or other governmental program for this prescription or where otherwise prohibited by law in your state; and you will otherwise comply with the terms mentioned herein.

To the Pharmacist: When you use this card, you are certifying that you have not submitted and will not submit a claim for reimbursement under any federal, state or other governmental program for this prescription.

  • Submit transaction to McKesson Corporation using BIN #610524
  • If primary commercial prescription insurance exists, input card information as secondary coverage and transmit using the COB segment of the NCPDP transaction. Applicable discounts will be displayed in the transaction response
  • Acceptance of this card and your submission of claims for the program are subject to the LoyaltyScript® program terms and conditions posted at mckesson.com/mprstnc
  • Patient is not eligible if prescriptions are paid in part or full by any state or federally funded health care program, including but not limited to Medicare, Medicaid, VA, DOD, or TRICARE, or where prohibited by law
  • For questions regarding setup, claim transmission, patient eligibility, or other issues, call the LoyaltyScript® Savings Card program at 1-866-355-9293, 8 AM–8 PM ET, Monday–Friday

Sunovion reserves the right to rescind, revoke, or amend this offer at any time without notice.


footer-cta-patient-support

Support Your Patients

Savings, support, and tools are available for your patients. Get the support they need.

footer-cta-patient-profiles

Explore Patient Profiles

What do patients like yours experience every day? Take a deeper look.

footer-cta-peers

Your Peers are Talking

Take a deep dive into bipolar depression, LATUDA and more

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR LATUDA

INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS; and SUICIDAL THOUGHTS AND BEHAVIORS

Increased Mortality in Elderly Patients with Dementia-Related Psychosis
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. LATUDA is not approved for the treatment of patients with dementia-related psychosis.

Suicidal Thoughts and Behaviors
Antidepressants increased the risk of suicidal thoughts and behavior in pediatric and young adults in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors.

 

CONTRAINDICATIONS: LATUDA is contraindicated in the following:

Cerebrovascular Adverse Reactions, Including Stroke: In clinical trials, elderly subjects with dementia randomized to risperidone, aripiprazole, and olanzapine had a higher incidence of stroke and transient ischemic attack, including fatal stroke. LATUDA is not approved for the treatment of patients with dementia-related psychosis.

Neuroleptic Malignant Syndrome (NMS): NMS is a potentially fatal symptom complex reported with administration of antipsychotic drugs. Clinical signs of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability. Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. Manage NMS with immediate discontinuation of antipsychotic drugs, including LATUDA, intensive symptomatic treatment and monitoring.

Tardive Dyskinesia (TD): The risk of developing TD (a syndrome of abnormal involuntary movements) and the potential for it to become irreversible are believed to increase as the duration of treatment and total cumulative dose of antipsychotic increase. The syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses or may even arise after discontinuation of treatment. The syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn.

Metabolic Changes Atypical antipsychotic drugs have caused metabolic changes including:

Hyperglycemia and Diabetes Mellitus: Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics. Patients with diabetes should be regularly monitored for worsening of glucose control; those with risk factors for diabetes should undergo fasting blood glucose testing at the beginning of and periodically during treatment. Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia, including polydipsia, polyuria, polyphagia, and weakness. Patients who develop symptoms of hyperglycemia should undergo fasting blood glucose testing. In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the suspect drug.

Dyslipidemia: Undesirable alterations in lipids have been observed in patients treated with atypical antipsychotics.

Weight Gain: Weight gain has been observed with atypical antipsychotic use. Clinical monitoring of weight is recommended.

Hyperprolactinemia: As with other drugs that antagonize dopamine D2 receptors, LATUDA elevates prolactin levels. Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds.

Leukopenia, Neutropenia, and Agranulocytosis: Leukopenia/neutropenia has been reported with antipsychotics. Agranulocytosis (including fatal cases) has been reported with other agents in the class. Monitor complete blood count in patients with a pre-existing low white blood cell count (WBC)/absolute neutrophil count (ANC) or history of drug-induced leukopenia/neutropenia. Discontinue LATUDA at the first sign of a decline in WBC in the absence of other causative factors.

Orthostatic Hypotension and Syncope: Atypical antipsychotics cause orthostatic hypotension and syncope. Generally, the risk is greatest at the beginning of treatment and when increasing the dose. Monitor patients vulnerable to hypotension and those with cardiovascular and cerebrovascular disease.

Falls: Antipsychotics may cause somnolence, postural hypotension, or motor and sensory instability, which may lead to falls, causing fractures or other injuries. For patients with disease, conditions, or medications that could exacerbate these effects, complete fall risk assessments when initiating treatment and recurrently during therapy.

Seizures: LATUDA should be used cautiously in patients with a history of seizures or with conditions that lower seizure threshold.

Potential for Cognitive and Motor Impairment: Patients should be cautioned about operating hazardous machinery, including motor vehicles, until they are reasonably certain that therapy with LATUDA does not affect them adversely.

Body Temperature Regulation: Use LATUDA with caution in patients who may experience conditions that increase body temperature (e.g., exercising strenuously, exposure to extreme heat, concomitant medication with anticholinergic activity, or being subject to dehydration).

Dysphagia: Antipsychotics, including LATUDA, have been associated with esophageal dysmotility and aspiration, and should be used with caution in patients at risk for aspiration pneumonia.

Most Commonly Observed Adverse Reactions: Commonly observed adverse reactions (≥5% incidence and at least twice the rate of placebo) for LATUDA:

To report SUSPECTED ADVERSE REACTIONS, contact Sunovion Pharmaceuticals Inc. at 877-737-7226 or FDA at 1-800-FDA-1088 (www.fda.gov/medwatch).

Indications

LATUDA is indicated for:

Before prescribing LATUDA, please read the full Prescribing Information, including Boxed Warning.